What baseline screening tests are recommended before initiating JAK inhibitor therapy in a patient with autoimmune alopecia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Baseline Screening Tests Before JAK Inhibitor Therapy for Alopecia Areata

Before initiating JAK inhibitor therapy in a patient with autoimmune alopecia, you must perform: complete blood count with differential, comprehensive metabolic panel (liver and renal function tests), lipid panel, tuberculosis screening (T-SPOT or QuantiFERON with chest imaging if positive), hepatitis B and C serology, HIV testing, and syphilis screening (TPPA), along with baseline skin examination for malignancy risk. 1, 2

Required Laboratory Tests

The 2025 expert consensus on JAK inhibitors provides the framework for baseline screening 1:

Core Laboratory Panel

  • Complete blood count with differential - Essential for baseline hematologic assessment
  • Liver function tests (AST/ALT at minimum, though full panel including bilirubin, albumin, alkaline phosphatase, and GGT is comprehensive)
  • Renal function tests (creatinine, BUN)
  • Lipid panel - JAK inhibitors can affect lipid metabolism

Infectious Disease Screening

Real-world data from 218 alopecia areata patients demonstrates the critical importance of infectious screening 2:

  • Tuberculosis: 37 of 218 patients (17%) had positive T-SPOT testing or chest imaging findings suggesting TB - this is a substantial proportion requiring screening
  • Hepatitis B surface antigen: 10 of 218 patients (4.6%) were positive
  • Hepatitis C antibodies: Screen all patients
  • HIV antibody: Screen all patients
  • Syphilis (TPPA): 3 of 218 patients (1.4%) were positive
  • Thyroid function (TSH): 9 of 176 tested patients (5.1%) had abnormalities - particularly relevant given autoimmune comorbidity patterns

Risk Factor Assessment

Beyond laboratory tests, document specific risk factors 1:

Cardiovascular and Thrombotic Risk

  • History of venous thromboembolism (VTE) - distinguish provoked vs. unprovoked events
  • Prior cardiovascular events (MI, stroke)
  • Smoking history - increases both cardiovascular and malignancy risk, particularly lung cancer
  • Age >50 years with cardiovascular risk factors (relevant from ORAL Surveillance trial subanalyses)

Malignancy Screening

  • Baseline skin examination for non-melanoma skin cancer, especially in high-risk patients
  • Document smoking history for lung cancer risk stratification

Other Considerations

  • History of herpes zoster - JAK inhibitors increase reactivation risk
  • History of complicated diverticulitis
  • Hepatitis B core antibody if surface antigen negative (for reactivation risk)

Monitoring Schedule

After baseline screening, establish periodic monitoring 1:

  • CBC with differential, liver/renal tests, lipids at regular intervals (specific frequency depends on individual risk factors and institutional protocols)
  • Skin examinations per national recommendations (not necessarily annual - adjust to local risk profiles)
  • Do NOT rely on CRP/ESR for disease activity monitoring, as JAK inhibitors suppress IL-6 signaling and artificially lower these markers independent of true disease control

Critical Pitfalls to Avoid

  1. Incomplete TB screening: With 17% positivity rate in real-world AA cohorts, this cannot be skipped 2
  2. Missing hepatitis B screening: Reactivation risk is real and preventable with proper screening
  3. Overlooking thrombotic risk factors: The ORAL Surveillance trial highlighted VTE concerns, making this assessment non-negotiable 1
  4. Inadequate smoking history: Affects both cardiovascular and malignancy risk stratification
  5. Using CRP/ESR for treatment response: These will decrease regardless of clinical improvement due to IL-6 pathway inhibition 1

The evidence strongly supports comprehensive baseline screening before JAK inhibitor initiation in alopecia areata patients, with particular emphasis on infectious disease screening given the real-world prevalence of latent infections in this population 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.